Taflotan: Uses, Dosage & Side Effects

What Is Taflotan and What Is It Used For?

Taflotan contains the active substance tafluprost, a synthetic fluorinated analogue of prostaglandin F2-alpha. Prostaglandin analogues are widely recognized as first-line pharmacological therapy for glaucoma and ocular hypertension according to international guidelines from the European Glaucoma Society (EGS), the American Academy of Ophthalmology (AAO), and the World Glaucoma Association (WGA). Tafluprost was specifically developed to combine potent IOP-lowering efficacy with the practical advantage of stability at room temperature after initial opening, and is available in a preservative-free formulation that reduces the risk of ocular surface irritation associated with long-term use of preserved eye drops.

The primary mechanism of action of tafluprost involves selective agonism at the prostaglandin FP receptor located in the ciliary muscle and trabecular meshwork of the eye. When tafluprost binds to these receptors, it triggers a cascade of intracellular events that lead to relaxation and remodeling of the extracellular matrix within the ciliary muscle. This structural change increases the permeability of the uveoscleral outflow pathway, which is the secondary route by which aqueous humor drains from the anterior chamber of the eye. By enhancing this drainage, the overall intraocular pressure is reduced. Some evidence also suggests a modest effect on the conventional trabecular meshwork outflow, further contributing to IOP lowering.

After topical application to the eye, tafluprost penetrates through the cornea and is rapidly hydrolyzed by corneal esterases into its biologically active metabolite, tafluprost acid. The IOP-lowering effect typically begins within 2 to 4 hours of instillation, with the maximum effect occurring at approximately 12 hours post-dose. The effect is sustained for at least 24 hours, which allows convenient once-daily dosing. Clinical studies have demonstrated that tafluprost reduces IOP by approximately 6 to 8 mmHg from baseline when used as monotherapy, which represents a reduction of roughly 25 to 35 percent from untreated baseline values.

Taflotan is specifically approved for the reduction of elevated intraocular pressure in adult patients with the following conditions:

• Open-angle glaucoma: This is the most common form of glaucoma, in which the drainage angle of the eye remains anatomically open but the trabecular meshwork becomes increasingly resistant to aqueous humor outflow over time. Without treatment, the resulting elevated IOP gradually damages the optic nerve fibers, leading to progressive and irreversible visual field loss. Open-angle glaucoma typically develops slowly and without symptoms in its early stages, which is why regular eye examinations are crucial for early detection.
• Ocular hypertension: This condition is defined as IOP consistently measured above the statistically normal range (typically above 21 mmHg) without any detectable optic nerve damage or visual field loss. Patients with ocular hypertension are considered at increased risk of developing glaucoma. Depending on the overall risk profile (including IOP level, central corneal thickness, age, and family history), treatment with IOP-lowering medications such as Taflotan may be initiated to reduce the risk of progression to glaucoma.

Glaucoma is a leading cause of irreversible blindness worldwide, affecting an estimated 80 million people globally. The World Health Organization identifies it as a priority eye disease. While elevated IOP is the most significant modifiable risk factor, glaucoma is a multifactorial disease involving vascular, genetic, and structural components. Lowering IOP remains the only proven strategy to slow or prevent the progression of glaucomatous optic neuropathy. Every 1 mmHg reduction in IOP has been shown to reduce the risk of disease progression by approximately 10 percent, according to landmark clinical trials such as the Early Manifest Glaucoma Trial (EMGT) and the Ocular Hypertension Treatment Study (OHTS).

What Should You Know Before Using Taflotan?

Contraindications

There are specific situations in which Taflotan must not be used. Understanding these absolute contraindications is essential before beginning treatment with this medication.

• Hypersensitivity: Do not use Taflotan if you are allergic (hypersensitive) to tafluprost or any of the other ingredients in the product, including glycerol, sodium dihydrogen phosphate dihydrate, disodium edetate, polysorbate 80, hydrochloric acid, sodium hydroxide, and water for injections. Allergic reactions can range from mild local irritation to more severe systemic reactions.

Warnings and Precautions

Before and during treatment with Taflotan, inform your doctor if any of the following conditions apply to you:

• Iris pigmentation changes: Tafluprost may gradually increase the brown pigment (melanin) in the iris of the treated eye. This is most apparent in patients with mixed-color irises (blue-brown, grey-brown, yellow-brown, or green-brown). The change occurs slowly, over months to years, and may be permanent. Patients with uniformly colored eyes (blue, grey, green, or brown) have a lower risk but are not exempt from this effect. In patients being treated in only one eye, the color difference between the two eyes may become noticeable. Once treatment is discontinued, no further increase in pigmentation has been observed, but the existing color change typically does not reverse.
• Periorbital and eyelid changes: Tafluprost can cause darkening of the eyelid skin and the skin around the treated eye. It may also cause increased length, thickness, color, and number of eyelashes, as well as abnormal hair growth on the eyelids. These effects may be partially reversible upon discontinuation but may persist in some patients. To minimize the risk of skin darkening, carefully wipe away any excess solution that contacts the skin around the eye after instillation.
• Kidney problems: Inform your doctor if you have impaired kidney function (renal impairment). There is limited clinical data on the use of tafluprost in patients with significant renal disease, and caution is warranted.
• Liver problems: Inform your doctor if you have impaired liver function (hepatic impairment). Although tafluprost is primarily metabolized locally in the eye, systemic exposure may be affected by liver function. Clinical data in this population is limited.
• Asthma: Prostaglandin analogues may theoretically exacerbate asthma symptoms. If you have asthma or a history of reactive airway disease, discuss this with your doctor before starting Taflotan. While respiratory side effects with topical ophthalmic prostaglandin analogues are uncommon, cases of worsening asthma and dyspnea have been reported.
• Other eye conditions: Use Taflotan with caution if you have inflammatory eye conditions (e.g., iritis, uveitis), aphakia (absence of the natural lens), pseudophakia with a torn posterior lens capsule, or known risk factors for cystoid macular edema. Prostaglandin analogues may increase the risk of macular edema in these populations.
• Severely damaged cornea: If you have a severely damaged cornea, the phosphate contained in Taflotan may, in very rare cases, cause cloudy deposits on the cornea due to calcium accumulation (corneal calcification) during treatment.

Your ophthalmologist will perform regular eye examinations, including assessment of IOP, optic nerve appearance, visual field testing, and evaluation of the ocular surface, to monitor both the effectiveness and safety of your treatment.

Pregnancy and Breastfeeding

Taflotan should not be used during pregnancy. Prostaglandin analogues have pharmacological activity that may affect pregnancy, and animal reproductive studies have shown adverse effects at doses higher than the clinical dose. If you are a woman of childbearing potential, you must use effective contraception during treatment with Taflotan. If you discover that you are pregnant while using this medication, discontinue it immediately and consult your doctor.

Taflotan should not be used while breastfeeding. It is not known whether tafluprost or its metabolites are excreted in human breast milk, and a risk to the nursing infant cannot be excluded. If treatment with Taflotan is essential, your doctor will advise you on whether to discontinue breastfeeding or to use an alternative medication.

Children and Adolescents

Taflotan is not recommended for use in children or adolescents under 18 years of age. There is insufficient clinical data on the safety and efficacy of tafluprost in this age group. Pediatric glaucoma is a complex condition that requires specialized management by a pediatric ophthalmologist.

Driving and Operating Machinery

Taflotan has no significant effect on the ability to drive or operate machinery under normal conditions. However, as with any eye drop, you may experience temporary blurred vision immediately after instillation. If your vision is blurred after applying the drops, do not drive or operate machinery until your vision has cleared. This blurring typically resolves within a few minutes.

How Does Taflotan Interact with Other Drugs?

Because tafluprost is administered topically to the eye and undergoes rapid local metabolism with very low systemic absorption, the risk of clinically significant systemic drug interactions is minimal. Plasma concentrations of tafluprost acid (the active metabolite) are typically below the limit of quantification within 30 minutes of ocular administration. Nevertheless, there are important considerations when using Taflotan alongside other ophthalmic medications or in certain clinical situations.

No formal interaction studies have been specifically conducted with Taflotan and systemic medications. Based on the pharmacological profile and very low systemic exposure, tafluprost is not expected to affect or be affected by orally administered drugs, including common cardiovascular medications, diabetes treatments, or analgesics. However, as with all medications, inform your doctor about your complete medication list.

Major Interactions

Minor Interactions

Taflotan is frequently used as part of multi-drug IOP-lowering regimens for patients whose glaucoma is not adequately controlled with a single medication. The combination of a prostaglandin analogue (such as tafluprost) with a beta-blocker, carbonic anhydrase inhibitor, or alpha-2 agonist is well established in clinical practice and supported by major glaucoma treatment guidelines. When using multiple eye drops, always apply Taflotan first and wait at least 5 minutes before instilling the next medication to prevent washout and ensure optimal absorption of each drug.

What Is the Correct Dosage of Taflotan?

Taflotan should always be used exactly as prescribed by your doctor or pharmacist. The dosage regimen for tafluprost is straightforward compared to many other medications, but correct administration technique is essential to ensure the full therapeutic benefit is delivered to the eye.

Adults

The evening dosing schedule is preferred because prostaglandin analogues achieve their peak IOP-lowering effect approximately 12 hours after administration, which coincides with the early morning hours when IOP is typically at its highest (the diurnal IOP peak). Consistent timing of administration is important for maintaining a stable and predictable IOP-lowering effect throughout the 24-hour period.

How to Use Single-Dose Containers

Taflotan sine is supplied in single-dose containers packed in sealed foil pouches. Proper handling is important to maintain sterility and product stability. Follow these steps each time you use the drops:

1. Wash your hands thoroughly before handling the eye drops to minimize the risk of contamination.
2. Remove the strip of single-dose containers from the foil pouch. Tear off one single-dose container from the strip. Return the remaining containers to the pouch and fold the edge to close it.
3. Ensure the solution is at the bottom of the single-dose container by gently shaking or tapping it before opening.
4. Twist off the tab to open the container. Do not touch the tip of the container with your fingers or any surface.
5. Tilt your head back and look upward. Hold the container tip close to the eye but do not let it touch the eye or eyelashes.
6. Gently pull down the lower eyelid with a clean finger to create a small pocket between the eyelid and the eye.
7. Squeeze the container gently and let one drop fall into the space between the lower eyelid and the eye.
8. Close your eye gently and press a finger against the inner corner of the eye (near the nose) for approximately one minute. This technique, called punctal occlusion, helps prevent the drop from draining into the tear duct and entering the bloodstream, thereby reducing systemic absorption and the risk of systemic side effects.
9. Wipe away any excess solution that may have run onto the skin around the eye. This helps reduce the risk of skin darkening (periorbital hyperpigmentation).
10. If a drop misses the eye, try again with a new drop.

If your doctor has prescribed Taflotan for both eyes, repeat the procedure for the second eye using the same single-dose container. The contents of one container are sufficient for both eyes. Discard the opened container immediately after use, even if there is solution remaining, as preservative-free formulations must not be reused once opened.

Elderly Patients

Missed Dose

If you forget to use Taflotan at your usual time, apply a single drop as soon as you remember, and then return to your normal dosing schedule the following evening. Do not apply a double dose to make up for the missed one. If you miss a dose entirely and it is already time for the next scheduled dose, simply skip the missed dose and continue with your regular routine. Occasional missed doses are unlikely to cause significant fluctuations in IOP, but consistent daily use is important for optimal disease management.

Overdose

If you accidentally apply more drops than prescribed, it is unlikely to cause serious harm. Excess solution will drain from the eye naturally. You may experience temporary eye irritation or redness. Simply apply your next dose at the usual scheduled time. If Taflotan is accidentally swallowed (for example, by a child), contact a doctor or poison control center immediately for assessment. Oral ingestion is not expected to cause significant toxicity based on the small quantity of active substance in each container, but medical evaluation is recommended as a precaution.

Stopping Treatment

What Are the Side Effects of Taflotan?

Like all medicines, Taflotan can cause side effects, although not everyone experiences them. Most side effects are local (affecting the eye and the area around it) and are generally mild to moderate in severity. Systemic side effects are uncommon due to the low systemic absorption of topically applied tafluprost. If you notice any unusual symptoms or if side effects become troublesome, contact your doctor or pharmacist for advice.

The side effects of Taflotan are classified below according to how frequently they occur. These frequency categories are based on clinical trial data and post-marketing surveillance reports.

It is important to understand that some side effects of prostaglandin analogues, including tafluprost, may develop gradually over weeks to months of treatment. Iris color change, for example, typically becomes apparent after several months of use and progresses slowly. Eyelash changes are usually noticed within the first few months of treatment. These changes are more prominent in the treated eye, which can create a cosmetic asymmetry if only one eye is being treated.

The risk of macular edema is particularly relevant for patients who are aphakic (lacking a natural lens), pseudophakic with a disrupted posterior lens capsule, or who have risk factors for macular edema such as a history of retinal vein occlusion or diabetic retinopathy. If you notice a decrease in your central vision or distortion while using Taflotan, contact your ophthalmologist promptly for evaluation.

Deepening of the eyelid sulcus (also described as periorbital fat atrophy or prostaglandin-associated periorbitopathy, or PAP) is a recognized class effect of prostaglandin analogue eye drops. It can cause the upper eyelid to appear more retracted or the eye to appear more sunken. This effect is generally reversible upon discontinuation of the medication, although complete resolution may take several months.

How Should You Store Taflotan?

Proper storage of Taflotan is essential to maintain the stability, sterility, and efficacy of the medication. Because the single-dose formulation (Taflotan sine) is preservative-free, it is particularly important to follow storage instructions carefully to prevent microbial contamination and chemical degradation.

Do not use Taflotan after the expiry date printed on the single-dose container, foil pouch, and outer carton (marked “EXP”). The expiry date refers to the last day of that month. When you first open a new foil pouch, write the date of opening in the space provided on the pouch so you can easily track the 28-day use-by period.

Keep this medicine out of the sight and reach of children at all times. Do not dispose of unused medicines via wastewater or household waste. Return unused or expired medication to your pharmacist for proper disposal. These measures help protect the environment.

What Does Taflotan Contain?

Understanding the full composition of Taflotan is important, particularly if you have known allergies or sensitivities to any pharmaceutical ingredients. The formulation has been designed to be preservative-free in the single-dose presentation (Taflotan sine), which is advantageous for long-term ocular surface health.

Taflotan is presented as a clear, colorless solution supplied in plastic single-dose containers. Each single-dose container holds 0.3 mL of solution. Ten containers are packed in a sealed foil pouch, and the product is available in cartons containing 30 or 90 single-dose containers (3 or 9 foil pouches). Not all pack sizes may be marketed in every country.

The marketing authorization for Taflotan is held by Santen Oy, based in Tampere, Finland, a pharmaceutical company specializing in ophthalmology. The product is manufactured at Santen’s facilities in Tampere. The medication is approved throughout the European Economic Area and in many other countries worldwide. In some countries, it is marketed under the brand name Saflutan (including Belgium, France, Ireland, Italy, Spain, and the United Kingdom, among others).